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Is there a difference between Parkinson disease patients and a control group in terms of
urinary symptoms and quality of life?
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Background/aim: The aim of this study is to research whether urinary symptoms and disruption of quality of life observed in Parkinson
disease patients are different than those of their healthy peers. Additionally, whether these complaints were affected by characteristics
such as age at onset of Parkinson disease, sex, disease duration, and severity was investigated.
Materials and methods: This study comprised a total of 79 individuals, 39 Parkinson patients and a control group of 40 individuals.
Parkinson diagnosis was provided by a neurology expert according to the UK Parkinson’s Disease Society Brain Bank Criteria. All patients
were evaluated by a urologist with the International Prostate Symptom Score (IPSS) and an overactive bladder (OAB) questionnaire.
Results: Compared with the control group, the Parkinson patient group had statistically significantly higher rates of urological
complaints (P < 0.001), irritative symptoms (P < 0.001), voiding symptoms (P < 0.001), OAB score (P < 0.001), IPSS total score (P =
0.007), and treatment requirements (P < 0.001).
Conclusion: Urologic complaints were observed more frequently in the Parkinson patient group compared to the control group.
Another important result of this study is that in the Parkinson patient group there was no difference found between urologic complaints
in terms of sex.
Key words: Parkinson disease, bladder dysfunction, lower urinary tract symptoms

1. Introduction
Parkinson disease (PD) is a chronic progressive disease
(1). Parkinson patients frequently have nonmotor
disorders such as constipation, sexual dysfunction, and
lower urinary tract symptoms, in addition to motor
disorders (2). Nonmotor disorders frequently observed
in PD patients include bladder dysfunctions like urgency
and frequent urination (3). The brain pathology causing
bladder dysfunction includes dopamine changes in the
basal ganglia-frontal circuit that normally suppresses
the urination reflex (1). Animal studies have shown a
correlation between dopaminergic degeneration in the
brain and overactive bladder (4).
The incidence of urinary complaints observed with
PD is reported as 93% (1,5). Among the most commonly
reported complaints are irritative bladder symptoms
like urgency, leaking, and frequent urination. Bladder
dysfunction increases related to the severity of PD (5).
Some studies have not found this correlation (1). Though
* Correspondence: drerdalbenli@gmail.com

PD patients generally respond very well to dopaminergic
medications, urological complaints generally do not
respond to medication treatment (6). Anticholinergic
medications frequently used for urinary complaints may
disrupt cognitive functions in older patients and it should
be remembered that they may cause serious results (7).
The aim of this study is to investigate whether there is a
difference between urinary complaints observed with PD
and disruption of quality of life caused by these complaints
in patients and healthy individuals. An additional aim was
to identify whether urinary complaints observed with
PD are affected by characteristics like sex, age, disease
duration, and severity.
2. Materials and methods
This study was completed at the Ordu University Hospital
with cooperation between the urology and neurology
clinics. This study included 39 patients applying to the
neurology clinic between January 2013 and June 2014 with
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a diagnosis of PD and a control group of 40 people (chosen
from patients’ relatives) for a total of 79 individuals.
Patients who could complete the survey forms themselves,
or with the help of family, were included in the study.
PD diagnosis was provided by a neurology expert
based on the UK Parkinson’s Disease Society Brain Bank
Criteria. The severity of disease was identified using the
Unified Parkinson’s Disease Rating Scale (UPDRS) and
Hoehn and Yahr scale (H & Y) (8,9). The study received
local ethics committee permission (number 2014/4).
Urological evaluation of individuals in the study, including
history, physical examination, and urine and blood tests,
was completed in the urology clinic. Urological complaints
were determined using the International Prostate Symptom
Score (IPSS) and overactive bladder (OAB) questionnaire
forms (10).
The IPSS questionnaire form comprises 7 questions
about urological complaints and one question about
quality of life. For each question, the patient is given a
score between 0 and 5 points and these scores are added
to obtain a total score. The total score varies from 0 to
35. According to the total score, urinary complaints are
classified as mild (0–7), moderate (8–19), and severe (20–

35). Quality of life (QoL) is evaluated by the last question
and severity of disruption of QoL is determined according
to points from 0 to 5 (no disruption to severe) (11).
3. Results
3.1. Sex difference and age
In the patient group 29 (74.4%) were male and 10 (25.6%)
female, while in the control group 27 (67.5%) were male
and 13 (32.5%) female. In the patient group, there were
no differences identified between the sexes in terms of
irritative (P = 0.095) and voiding (P = 0.94) complaints,
incontinence (P = 0.45), urgency (P = 0.21), nocturia (P
= 0.95), and treatment requirements due to urological
complaints (P = 0.75) (Table 1).
The comparison of female and male patients in the PD
group is shown in Table 2. The mean age of PD patients
was 69.7 ± 7.4 years, and the mean age was 67.9 ± 7.7 years
in the control group. In terms of age and sex, there was no
statistical difference identified between the PD and control
group (P = 0.284 and P = 0.777, respectively). There were
higher rates of urologic symptoms, irritative (storage)
complaints, voiding complaints, overactive bladder score,

Table 1. Comparison of LUTS between female patients and male patients with PD.
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Males (n = 29)

Females (n = 10)

P-value

Age (years), mean ± SD
Age at onset of disease, years
Duration of PD, years
Mean levodopa dosage (mg/day)
Stage of disease
1 (H & Y stage), n (%)
2 (H & Y stage), n (%)
3 (H & Y stage), n (%)
4 (H & Y stage), n (%)
UPDRS
UPDRS total
UPDRS cognitive
UPDRS motor sections
UPDRS activities of daily living
Urologic symptoms, n (%)
Irritative symptoms, n (%)
Voiding, n (%)
Nocturia, n (%)
Treatment needs, n (%)
IPSS total

68.90 ± 7.451
63.83 ± 8.477
5.10 ± 3.735
422.4 ± 252.1

72.40 ± 7.027
66.30 ± 7.973
6.10 ± 2.885
657.5 ± 371.3

0.10
0.22
0.29
0.05

10 (34.4)
10 (34.4)
9 (31.2)
0 (0)

3 (30)
4 (40)
2 (20)
1 (10)

23.5 ± 14.8
1.72 ± 1.16
17.6 ± 15.08
7.37 ± 7.83

23.8 ± 9.7
2.7 ± 1.33
15 ± 6.81
6.5 ± 2.59

0.58
0.04
0.93
0.36

20 (68)
17 (58.6)
20 (68.9)
19 (65.5)
9.9 ± 6.108

7 (70)
6 (60)
7 (70)
6 (60)
8.80 ± 6.143

0.95
0.94
0.95
0.75
0.53

QoL

2.34 ± 1.58

2.1 ± 1.59

0.76

0.36
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Table 2. Comparison of LUTS between Parkinson patients and control group.
LUTS

PD (n = 39)

Controls (n = 40)

P-value

Age, years
Sex, n (%)
Female
Male
Urologic symptoms, n (%)
Irritative symptoms, n (%)
Voiding symptoms, n (%)
Overactive bladder, n (%)
Urge incontinence, n (%)
Incontinence, n (%)
Nocturia, n (%)
Treatment needs, n (%)
IPSS total
QoL

69.79 ± 7.4
10 (25.6)
29 (74.4)
27 (69.2)
23 (59)
11 (28.2)
20 (51.3)
16 (41)
7 (17.9)
27 (69.2)
25 (64.1)
9.62 ± 6.05
2.28 ± 1.57

67.95 ± 7.7
13 (32.5)
27 (67.5)
3 (7.5)
1 (2.5)
2 (5)
2 (5)
3 (7.5)
0 (0)
25 (62.5)
4 (10)
5.18 ± 3.61
1.05 ± 1.19

0.284
0.777
0.777
<0.001
<0.001
0.005
<0.001
<0.001
0.005
0.450
<0.001
0.007
0.014

urge incontinence, incontinence, and treatment needs
among PD patients compared to controls (Table 2).
3.2. Comparison of PD and control groups
When total IPSS scores and QoL scores were compared
between the groups, they were significantly higher in
the PD patient group compared to the control group (P
= 0.007 and P=0.014, respectively). When IPSS subscores
were examined, the scores for question 2 (feeling of need
to urinate within 2 h of urination) (P = 0.03) and question
4 (urgency) (P = 0.08) were observed to be significantly
higher in the PD group. In terms of other IPSS questions,
there were no differences observed (P > 0.05). In the PD
patient group, irritative symptoms (P < 0.001), voiding
symptoms (P = 0.005), OAB score (P < 0.001), urgency (P
< 0.001), leaking (P = 0.005), and treatment requirements
due to urological complaints (P < 0.001) were found to be
significantly high compared to the control group.
3.3. Duration and severity
The duration of PD varied from 1 year to 15 years, with
a mean of 5.36 ± 3.52 years and median of 3 years. No
association between the duration of disease and total
IPSS score (r = 0.072; P = 0.663), QoL (r = –0.090; P =
0.586), irritative symptoms (r = 0.189; P = 0.250), and
voiding symptoms (r = 0.091; P = 0.580) was observed.
The UPDRS total scores varied from 8 to 60 with a mean
of 25.58 ± 113.58. There was no correlation found between
total UPDRS points and total IPSS score (r = 0.101; P =
0.539), QoL (r = 0.078; P = 0.528), and irritative symptoms
(r = 0.269; P = 0.098). There was no correlation between
total IPSS score (r= 0.008; P = 0.963), QoL (r= –0.194; P
= 0.236), and irritative symptoms (r = 0.002; P = 0.990)
and UPDRS motor points. There was no correlation found

between UPDRS cognitive score and total IPSS score (r =
0.073; P = 0.658) and QoL (r = 0.226; P = 0.167); however
there was a correlation found with irritative symptoms (r
= 0.447; P = 0.004) (Table 3).
3.4. Age at onset of disease
The age at onset of PD varied from 44 to 78 years and the
mean age at onset of PD was identified as 64.46 ± 8.31
years. There was no correlation found between disease
onset age and total IPSS score (r = 0.121; P = 0.464), QoL
(r = 0.185; P = 0.260), irritative symptoms (r = 0.130; P
= 0.431), and voiding symptoms (r = –0.116; P = 0.923)
(Table 4).
3.5. Disease stage (H & Y stage)
The distribution of PD patients according to stage is
as follows: 13 patients (33.3%) in stage 1, 14 (35.9%) in
stage 2, 11 (28.2%) in stage 3, and 1 (2.6%) in stage 4. The
majority of patients were in the early stages of the disease.
There was no correlation found between disease stage and
total IPSS score (r = 0.187; P = 0.253), QoL score (r = 0.078;
P = 0.637), and irritative symptoms (r = 0.363; P = 0.023).
4. Discussion
In our study lower urinary system symptoms (LUTS)
were identified more frequently in the PD patient group
compared to the control group. The IPSS total and QoL
scores showing severity of urological complaints were
observed to be higher in the PD group. The most common
urinary complaints in the PD group were irritative bladder
symptoms and these were identified significantly more
frequently compared to the control group. There was a
positive correlation identified between stage and severity
of PD and overactive bladder complaints.
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Table 3. Demographics and PD characteristic features of the patients.
PD (n = 39)
69.79 ± 7.41 (53–82)
29 (4.4)
10 (25.6)
64.46 ± 8.31 (44–78)
5.36 ± 3.52 (1–15)

Mean age, years (min–max)
Sex, n (%) male
female
Age at onset of disease, years (min–max)
Duration of PD, years (min–max)
Stage of disease
1 (H.Y.S.), n (%)
2 (H.Y.S.), n (%)
3 (H.Y.S.), n (%)
4 (H.Y.S.), n (%)
UPDRS (min–max)
UPDRS total
UPDRS cognitive
UPDRS motor sections
UPDRS activities of daily living

13 (33.3)
14 (35.9)
11 (28.2)
1 (2.6)
23.58 ± 13.58 (8–60)
1.97 ± 1.26 (0–5)
16.97 ± 13.41 (3–78)
7.15 ± 6.85 (0–28)

UPDRS: Unified Parkinson’s Disease Rating Scale, H.Y.S: Hoehn and Yahr scale.

IPSS scores are important to see the severity,
progression, and effect of treatment for urological
complaints. A 3-point reduction in IPSS score shows
that treatment is effective (11). The IPSS is mainly used
to evaluate obstructive complaints. In our study it was
used in both sexes to determine the effect of obstructive
symptoms in neurological disease. In the PD patient
group there was no difference identified between the sexes
in terms of IPSS total scores (P = 0.605). Expected to
increase linked to prostate disease in elderly male patients,
voiding (obstructive) complaints were found to be similar
in women. A study reported that this may be caused by
bradykinetic external sphincter and somatic pelvic muscle
dysfunction developing linked to neurological disease (12).
Though this questionnaire is not validated for women, we

used a single form for both sexes. The definition of OAB
includes complaints such as frequent urination, urgency,
and/or leaking. To assess OAB an 8-question OAB
questionnaire form was used. As OAB complaints may be
common symptoms in many diseases, it is necessary to
exclude causes such as underlying infection and bladder
tumors (13).
Though the IPSS form is generally used to assess
obstructive complaints caused by prostate hypertrophy in
men, in PD patients there was no difference in total IPSS
scores identified between the sexes. In a study comparing
total irritative and obstructive common urinary scores
between the sexes in PD by Campos-Sousa et al., they
reported no differences between the sexes (14). Similarly,
in our study, there were no differences identified between

Table 4. The correlation of nonmotor functions and clinical features in the Parkinson group.
(r / P)

IPSS total

QoL

IEFF

Voiding symptoms

Irritative symptoms

Age

0.163 / 0.320

0.165 / 0.314

–0.249 / 0.184

–0.059 / 0.719

0.0232 / 0.155

Disease duration

0.072 / 0.663

–0.090 / 0.586

–0.034 / 0.859

0.091 / 0.580

0.189 / 0.250

Age at onset

0.121 / 0.464

0.185 / 0.260

–0.213 / 0.258

–0.016 / 0.923

0.130 / 0.431

H&Y stage

0.187 / 0.253

0.078 / 0.637

0.001 / 0.998

0.072 / 0.664

0.363 / 0.023

UPDRS total

0.101 / 0.539

0.104 / 0.528

0.044 / 0.816

0.180 / 0.272

0.269 / 0.098

UPDRS motor

0.008 / 0.963

–0.194 / 0.236

0.027 / 0.887

0.019 / 0.906

0.002 / 0.990

UPDRS cognitive

0.073 / 0.658

0.226 / 0.167

0.091 / 0.631

0.204 / 0.214

0.447 / 0.004

UPDRS activities of daily living

0.073 / 0.658

0.226 / 0.167

0.091 / 0.631

0.204 / 0.214

0.447 / 0.004
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the sexes in PD patients in terms of irritative (P = 0.95)
and voiding (P = 0.94) symptoms. Additionally, there was
no difference identified between the sexes in terms of
total IPSS scores and QoL scores (P = 0.76). The reason
for this may be that our study excluded patients receiving
medication treatment for prostate disease or who had
undergone prostate surgery. Our results are in accordance
with the results of many studies, including those by Araki
et al. and Lemack et al. (14–16). The lack of differences
identified between women and elderly men, who are
expected to have more urological complaints linked to
prostate growth, is reported to be due to the contribution
of neurological changes occurring in PD to urinary
complaints (17,18). In our study the effect of PD is clearly
visible when compared with the control group (P < 0.001).
As reported in the literature, this suggests a relationship
between dopaminergic degeneration and LUTS (19). It
is reported to be difficult to determine the degree of the
effect of this damage on urological complaints (1).
Myers et al. reported a correlation between disease
onset age and irritative complaints in PD patients (20).
This result is supported by urodynamic studies showing
irritative complaints completed by Araki et al. (21).
However, there are studies reporting contradictory
results, including one by Sammour et al. (22). That study
reported that there was no relationship between voiding
dysfunction and disease onset age (P = 0.960). Our results
are in accordance with those of Sammour et al., showing
no correlation between disease onset age and irritative and
voiding complaints (P > 0.05).
In our study we did not find any correlation between
age and urological symptoms in the PD group (P > 0.05).
These results are in accordance with a study by Gray et al.
that reported that urological complaints were related to
age; however, age did not affect urological complaints (23).
In our study there was no correlation identified between
disease duration and irritative and voiding symptoms. Our
study results comply with the study by Compos-Sousa et
al., who reported no relationship between disease duration
and urinary symptoms (14). As reported by Diamond et al.
the reason for there being no relationship between disease
duration and urinary symptoms may be that each patient
has a different age at onset (24).
The severity of disease was assessed using H & Y staging
and UPDRS scales. Our findings show that as disease
stage and progression increase, the severity and frequency
of urologic complaints increase. Disease progression
is related more to OAB symptoms like urgency and
leaking. A study using urodynamic methods reported that
urinary complaints increased with progression of PD, in
accordance with the results of our study (16). Additionally,
we identified a positive correlation between UPDRS
cognitive and UPDRS daily life scores with irritative

complaints (P = 0.004). These results are in accordance
with the results of studies by many researchers like Araki
and Kuno and Sammour et al. (16,22). The researchers
reported that severity of urinary complaints increased
with disease progression. It was also reported that UPDRS
score is associated with erection and lubrication (25).
Comparing the PD and control groups, urinary
complaints were identified significantly more frequently
in the PD patient group. The most frequently encountered
urinary complaints in the PD patient group were OAB
complaints like urgency, frequent urination, and leaking
(P < 0.001). After irritative symptoms, the most frequently
observed complaints in the PD group were voiding
complaints and this rate was 59%, while in the control
group this rate was 2.5% (P < 0.001). While the incidence
of urological complaints in the PD group was 69.2%, this
rate was 7.5% in the control group and these results are in
accordance with rates reported in the literature (27%–75%)
(13,15). The reason for such a broad interval of incidence
rates in the literature may be due to patient selection
criteria in urology and neurology clinics. Due to difficulty
in understanding the questionnaire form, and due to the
chronic nature of PD, patients are in close contact with
doctors and may have had help from doctors in filling in
the form (15,26). The IPSS total score and QoL in the PD
group were negatively affected compared to the control
group. These patients felt they required more treatment
to resolve their urologic complaints (P < 0.001). Many
studies comply with our results, reporting that urological
complaints disrupt the QoL of patients (16,27). There was
no difference identified between the groups in terms of
nocturia (nighttime urination frequency > 1) (P = 0.450).
The reason for increased urological complaints in PD
patients has been broadly examined in the literature and
studies have reported the role of the dopaminergic system
in neurogenic control of the bladder. Symptoms such as
urgency, frequent urination, and nocturia, suggesting an
OAB due to reduction in dopaminergic functions of the
nigrostriatal area, are more commonly encountered in PD
(28). Additionally, studies have reported that the severity
of urinary dysfunction in PD is related to the scale of
dopamine degeneration, stage of disease, and neurological
deficit (29). A study by Winge et al. identified a correlation
between urological complaints and reduction in total
counts of dopaminergic neurons and caudate degeneration
(30). The results of the study reported that reduced cortical
stimulation from the basal ganglions is a significant cause
of urinary symptoms in PD disease. The same study found
the dopaminergic medications used for treatment had no
effect on resolving or reducing urological complaints.
The limitations of our study are linked to the low
number of patients. Another limitation is that advanced
assessments such as uroflowmetry, urodynamics, and
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cystoscopy were not performed for detailed evaluation
of patient. Another deficient point of the study is that for
patients requiring treatment results after treatment are not
known.
In conclusion, in our study, urological complaints were
observed more frequently in PD patients compared to the
control group. The most commonly observed symptoms
were irritative urination symptoms such as urgency and
leaking, immediately followed by voiding symptoms. An
interesting point of the study is that no difference was found

between women and men, though voiding complaints
are expected to be more common in men due to prostate
disease. The majority of PD patients believe that urological
complaints are a result of the neurological disease and
think they must live with it and do not share their
complaints with doctors. As a result, PD patients should
be routinely questioned about urological symptoms and
necessary precautions should be taken. This is important
both to improve the QoL of patients and to prevent serious
problems that may develop in the future.
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